The Melanocortin Melanocyte-Stimulating Hormone/Adrenocorticotropin4–10Decreases Body Fat in Humans1
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The control of body fat is a prominent factor in human health. Animal studies have indicated a homeostatic central nervous system regulation of body fat with particular involvement of the melanocortin receptor pathway. This study provides evidence for a similar role for melanocortins in the long-term control of fat stores in humans. Thirty-six normal weight humans were assigned to one of three experimental groups. After a 4-week baseline, one group was treated with MSH/ACTH(4-10) (MSH/ACTH(4-10)) representing the core sequence of all melanocortins. Another group received desacetyl-alphaMSH, a selective agonist of the brain melanocortin-4 receptor, which shares the 4-10 sequence with MSH/ACTH(4-10). The third group received placebo. Treatments were given intranasally twice daily for 6 weeks, at equimolar doses (MSH/ACTH(4-10), 0.5 mg; desacetyl-alphaMSH, 0.84 mg). Body weight, body composition, and plasma hormone concentrations were measured before and after treatment. MSH/ACTH(4-10) reduced body fat, on the average, by 1.68 kg (P < 0.05) and body weight by 0.79 kg (P < 0.001). Concurrently, plasma leptin levels were decreased by 24% (P < 0.02), and insulin levels were decreased by 20% (P< 0.05) after MSH/ACTH(4-10). Changes after desacetyl-alphaMSH remained nonsignificant. The finding of reduced body adiposity after MSH/ACTH(4-10) confirms and extends to the human the findings of animal models indicating an essential role of the hypothalamic melanocortin system in body weight control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030 · cited 1×
“Thus, genetic deficiency of the MC4-R in mice is accompanied by hyperphagia, hyperinsulinemia, hyperglycemia, and obesity (13, 14).”
Assessment of fat-free mass using bioelectrical impedance measurements of the human body
Lukaski, H., Johnson, P., Bolonchuk, W., & Lykken, G. (1985) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/41.4.810 · Cited by 1,896
Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein
Ollmann, M. M., Wilson, B. D., Yang, Y.-K., Kerns, J. A., Chen, Y., Gantz, I., & Barsh, G. S. (1997) · Science · doi:10.1126/science.278.5335.135 · Cited by 1,881
Cerebrospinal fluid leptin levels: Relationship to plasma levels and to adiposity in humans
Schwartz, M. W., Peskind, E., Raskind, M., Boyko, E. J., & Porte, D. (1996) · Nature Medicine · doi:10.1038/nm0596-589 · Cited by 1,014
(1996) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/64.3.524s · Cited by 549
Sipols, A. J., Baskin, D. G., & Schwartz, M. W. (1995) · Diabetes · doi:10.2337/diab.44.2.147 · Cited by 389
Balin, B. J., Broadwell, R. D., Salcman, M., & El‐Kalliny, M. (1986) · Journal of Comparative Neurology · doi:10.1002/cne.902510209 · Cited by 358
Schaefer, F., Georgi, M., Zieger, A., & Schärer, K. (1994) · Pediatric Research · doi:10.1203/00006450-199405000-00016 · Cited by 260 · cited 1×
“Bioelectric impedance analysis predicts fat and fat-free mass with a precision similar to that of conventional anthropometry, using published equations to estimate body composition from skinfold measurements (37).”
Eating disorders: Progress and problems
Walsh, B. T., & Devlin, M. J. (1998) · Science · doi:10.1126/science.280.5368.1387 · Cited by 197
Cited by
Sniffing neuropeptides: A transnasal approach to the human brain
Born, J., Lange, T., Kern, W., McGregor, G. P., Bickel, U., & Fehm, H. L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-849 · Cited by 1,356
Self-citationIntranasal delivery to the central nervous system: Mechanisms and experimental considerations
Dhuria, S. V., Hanson, L. R., & Frey, W. H. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21924 · Cited by 1,239
“The weight regulatory peptide, melanocortin, reaches the CSF in humans within minutes of intranasal administration, without affecting blood concentrations,(19) and decreases body weight in normal volunteers after chronic intranasal administration for 6 weeks.(25) The peptide hormone, oxytocin, has been intranasally de…”
BackgroundIntranasal delivery of biologics to the central nervous system
Lochhead, J. J., & Thorne, R. G. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.002 · Cited by 1,214
Nasal drug delivery—possibilities, problems and solutions
Illum, L. (2003) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00363-2 · Cited by 1,102
Evaluation of intranasal delivery route of drug administration for brain targeting
Erdő, F., Bors, L. A., Farkas, D., Bajza, Á., & Gizurarson, S. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2018.10.009 · Cited by 744
Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives
UGWOKE, M., AGU, R., VERBEKE, N., & KINGET, R. (2005) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2005.07.009 · Cited by 543
Pardeshi, C. V., & Belgamwar, V. S. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.790887 · Cited by 482
Is nose-to-brain transport of drugs in man a reality?
Illum, L. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357022539 · Cited by 439
Genetics and Pathophysiology of Human Obesity
Cummings, D. E., & Schwartz, M. W. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152403 · Cited by 372
The role of proopiomelanocortin (POMC) neurones in feeding behaviour
Millington, G. W. (2007) · Nutrition & Metabolism · doi:10.1186/1743-7075-4-18 · Cited by 345
Krude, H., Biebermann, H., Schnabel, D., Tansek, M. Z., Theunissen, P., Mullis, P. E., & Grüters, A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030502 · Cited by 307
Pro-opiomelanocortin processing in the hypothalamus: impact on melanocortin signalling and obesity
Pritchard, L., Turnbull, A., & White, A. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1720411 · Cited by 297
Benedict, C., Kern, W., Schultes, B., Born, J., & Hallschmid, M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2606 · Cited by 296
Intranasal Insulin Reduces Body Fat in Men but not in Women
Hallschmid, M., Benedict, C., Schultes, B., Fehm, H.-L., Born, J., & Kern, W. (2004) · Diabetes · doi:10.2337/diabetes.53.11.3024 · Cited by 281
Self-citationChronobiology in the endocrine system
Haus, E. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.01.001 · Cited by 225
“This difference is due to a higher circadian and a higher circannu reported for vasopressin [78], a cholecystokinin analog [79], corticotrophin-releasing hormone [80], insulin [81], growth hormone releasing hormone [82], ACTH [83], MSH/ACTH [84], orexin [85], neuropeptides [86], and neuropeptide Y [87].”
BackgroundStrategies To Deliver Peptide Drugs to the Brain
Lalatsa, A., Schatzlein, A. G., & Uchegbu, I. F. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400680d · Cited by 160
The Neuroendocrine Circuitry Controlled by POMC, MSH, and AGRP
Biebermann, H., Kühnen, P., Kleinau, G., & Krude, H. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-24716-3_3 · Cited by 70
“The first study to reduce bodyweight in humans usesACTH4-10whichwas found to be effective in healthy adults (Fehm et al. 2001).”
Background
Metadata
- Authors
- Fehm, H. L., Smolnik, R., Kern, W., McGregor, G. P., Bickel, U., & Born, J.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2001-03
- Volume
- 86
- Issue
- 3
- Pages
- 1144-1148
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1995136165
- Cited by
- 113
- References
- 9
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.